Citius Oncology Inc (CTOR)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1111)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

최신 SEC 제출 서류

CTOR's Discussions on Twitter

Compare CTOR vs TAK, ZTS, HLN, TEVA, UTHR

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CTOR Citius Oncology Inc	1.22	104.16M	0	0	0	0.00
TAK Takeda Pharmaceutical Co Adr	18.46	58.03B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	126.65	55.37B	9.40B	2.65B	2.24B	5.935
HLN Haleon Plc Adr	11.20	49.70B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	33.98	39.50B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	473.66	20.50B	3.13B	1.27B	1.12B	26.39

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-09-23	업그레이드	Maxim Group	Hold → Buy
2024-11-27	개시	Maxim Group	Buy

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology Inc (CTOR) 재무 분석

Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Compare CTOR vs TAK, ZTS, HLN, TEVA, UTHR

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve

Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates - MarketBeat

Earnings Breakdown: Citius Oncology Q1 - Benzinga

Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire

Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI

Citius Oncology and Uniphar sign European distribution deal for Lymphir - Yahoo Finance

Citius Oncology inks exclusive European distribution pact with Uniphar - MSN

Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar - Finviz

Citius inks EU distribution agreement for CTCL treatment - The Pharma Letter

Biopharmaceutical company Citius Oncology announced that it has signed an exclusive distribution agreement with Europe's leading healthcare product provider Uniphar, officially expanding the commercialization of its innovative lymphoma therapy Lymphir - Bitget

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - Morningstar

Citius Oncology (CTOR) Projected to Post Quarterly Earnings on Friday - MarketBeat

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 22.3% in January - MarketBeat

Interleukin-2 (IL-2) Market to Grow Rapidly Over the Next Decade by 2034, DelveInsight Observes | Eisai, Citius Oncology, Corvus Pharmaceuticals, ILTOO Pharma - Barchart.com

CEO Moves: Why is Citius Oncology Inc stock going down2025 Trading Recap & Smart Investment Allocation Insights - baoquankhu1.vn

Aug Reactions: Can HCSG maintain sales growthJuly 2025 Setups & Growth Focused Investment Plans - baoquankhu1.vn

Decliners Report: Is Citius Oncology Inc undervalued by DCF analysisJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn

Why Citius Oncology Inc. stock attracts global investorsEarnings Risk Report & Reliable Trade Execution Plans - bollywoodhelpline.com

Dow Update: Why is Citius Oncology Inc stock going downWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn

Short Interest in Citius Oncology, Inc. (NASDAQ:CTOR) Expands By 51.2% - MarketBeat

Profit Review: Is Citius Oncology Inc likely to announce a buybackJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn

Citius Oncology, Inc. (NASDAQ:CTOR): Is Breakeven Near? - simplywall.st

Can Citius Oncology Inc. stock beat market expectations this quarterJuly 2025 Setups & Long-Term Capital Growth Strategies - Улправда

Does Citius Oncology Inc. stock trade at a discount to peersPrice Action & Daily Chart Pattern Signals - Улправда

How buybacks impact Citius Oncology Inc. stock valueEarnings Growth Report & Expert Curated Trade Setups - Улправда

Aug Sectors: Why Citius Oncology Inc. stock attracts global investorsTrade Analysis Report & Weekly Watchlist of Top Performers - Улправда

Citius Oncology, Inc.Common Stock (NQ: CTOR - FinancialContent

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus

Citius Oncology raises $18M through direct offering - MSN

News | postregister.comCitius Oncology, Inc.Common Stock (Nasdaq:CTOR) Price Chart - FinancialContent

Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - marketscreener.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - PR Newswire

Citius Oncology announces pricing of $9 million public offering - MSN

What drives Citius Oncology Inc stock priceVolatility Trading Techniques & You’ve Never Seen Stock Picks Like These - earlytimes.in

Is Citius Oncology Inc a good long term investmentBear Market Strategies & Low Entry Risk Stocks - earlytimes.in

Earnings Miss: Will Citius Oncology Inc stock sustain high P E ratiosJuly 2025 Institutional & Verified Technical Signals - Bộ Nội Vụ

Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Increase in Short Interest - Defense World

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - 富途牛牛

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat

Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga France

Citius Oncology’s Lymphir FDA win clouded by high upfront costs, regulatory risks, and uncertain market adoption - MSN

Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption - TipRanks

Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga

Citius Oncology, Inc. Full Year Loss Increases - Nasdaq

Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent

Citius Oncology (NASDAQ:CTOR) Issues Quarterly Earnings Results - MarketBeat

Citius Oncology Fiscal 2025 Loss Widens - marketscreener.com

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News

Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets

Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com

Citius Oncology Inc (CTOR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CTOR과 유사한 종목